Alnylam second quarter income decreases to $20.

Alnylam second quarter income decreases to $20.6 million Alnylam Pharmaceuticals, Inc . , a leading RNAi therapeutics company, reported its consolidated financial outcomes for the second quarter 2011 today, and company highlights. Alnylam remains focused and focused on the advancement of RNAi therapeutics as a whole new class of innovative medications. Our progress in the initial half of 2011 is exemplified by the continued advancement of our medical pipeline.

what is testosterone

Testing in mice that received the disease fighting capability booster injections demonstrated that amyloid plaque formation was 50 % to 70 % significantly less than in mice that received no therapy. Reductions in amyloid beta were almost the same for mice treated in early stages, at age 7 months, and before disease onset, compared to mice treated at age 11 months, which had mild dementia already. Immunostaining tests on mind tissue in treated mice demonstrated one to two instances fewer damaged neurons including disease-related tau aggregates than in untreated mice. Dementia-associated brain swelling was halved in treated mice also, the researchers statement, with ‘classic indicators of a normal immune response against both amyloid beta and tau proteins,’ as demonstrated by the current presence of immune system cytokines and T-helper cells.